Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina

Study Overview
=================
Brief Summary
-----------------
Atherosclerotic cardiovascular disease is a leading cause of mortality in our countries. Clinically, symptoms could be chest pain suggesting stable angina. Atherosclerosis is influenced by cardiovascular risk factors which obesity (Body Mass Index>30). Obesity is associated with an increase risk of cardiovascular complications. Lipoprotein(a) is regarded as an independent risk factor for premature cardiovascular disease. Lp(a) is composed of low-density lipoprotein - like particle bound to glycoprotein molecule: apolipoprotein(a). Plasma levels are determinated to more than 90% by genetic factors (no significant influence of statin, weight, lifestyle factor: diet, exercise). Two study with few patients have found that aspirin lowers serum Lp(a) levels. Elevated Lp(a) is a risk factor for recurrent coronary events in obese patient. Atherosclerosis is associated with imbalance of coagulation. TFPI (tissue factor pathway inhibitor) is the earliest inhibitor of the blood coagulation process, natural direct inhibitor of tissue factor. In-vitro, TFPI activity is inhibited by high Lp(a) . The aim of this study is to research reverse association between Lp(a) and TFPI activity in obese patient with chest pain like stable angina suggesting atherosclerotic heart disease and effect of aspirin.

Official Title
-----------------
Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major Men Obese BMI>30 No aspirin treatment before inclusion Coronary exploration: coronary angiography or tomography coronary angiography Chest pain like stable angina Exclusion Criteria: Women Severe hepatic insufficiency Inflammatory disease Neoplasia Protein S deficiency Aspirin treatment 10 days before inclusion Oral anticoagulant treatment at inclusion Heparin or low molecular weight heparin treatment at inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| obese men<br>obese men with chest pain like angina | Other: blood sample<br>* blood sample at inclusion and 1 month after inclusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between Lp(a) and TFPI activity | Establish correlation between Lp(a) rate and TFPI activity in obese patients with chest pain like stable angina | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Lp(a) and TFPI resistance | Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment | day 1 | 
| Correlation between lp(a) rate and TFPI activity | Establish the correlation, 1 month after initiation of aspirin treatment, between lp(a) rate and TFPI activity | 1 month | 
| thrombin generation | describe thrombin generation with calibrated automated thrombinography technique in obese patient with chest pain like angina and hight Lp(a)rate | day 1 | 
| Correlation between Lp(a) and TFPI resistance | Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
men, obesity, TFPI, Lipoprotein(a), Lp(a), Tissue Factor pathway inhibitor, aspirin